

Mahmoud M Shehata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1224184/publications.pdf>

Version: 2024-02-01

34
papers

1,569
citations

331670

21
h-index

377865

34
g-index

34
all docs

34
docs citations

34
times ranked

2110
citing authors

#	ARTICLE	IF	CITATIONS
1	Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection. <i>PLoS Pathogens</i> , 2022, 18, e1010219.	4.7	35
2	Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. <i>Frontiers in Microbiology</i> , 2021, 12, 611958.	3.5	12
3	Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. <i>PLoS Pathogens</i> , 2021, 17, e1009413.	4.7	21
4	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. <i>Vaccines</i> , 2021, 9, 214.	4.4	33
5	Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate. <i>Pathogens</i> , 2021, 10, 623.	2.8	44
6	Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. <i>Heliyon</i> , 2021, 7, e07962.	3.2	62
7	Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. <i>Bioorganic Chemistry</i> , 2021, 116, 105363.	4.1	10
8	In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine. <i>Molecules</i> , 2021, 26, 6182.	3.8	23
9	Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2. <i>Molecules</i> , 2021, 26, 6559.	3.8	54
10	PA from a Recent H9N2 (G1-Like) Avian Influenza A Virus (AIV) Strain Carrying Lysine 367 Confers Altered Replication Efficiency and Pathogenicity to Contemporaneous H5N1 in Mammalian Systems. <i>Viruses</i> , 2020, 12, 1046.	3.3	12
11	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. <i>Frontiers in Microbiology</i> , 2020, 11, 596851.	3.5	7
12	FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. <i>Pharmaceuticals</i> , 2020, 13, 443.	3.8	110
13	Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	44
14	Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science. <i>Microorganisms</i> , 2020, 8, 991.	3.6	30
15	Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. <i>PLoS ONE</i> , 2020, 15, e0241471.	2.5	11
16	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. <i>Viruses</i> , 2019, 11, 717.	3.3	38
17	NextGen Voices: Science-inspired sustainable behavior. <i>Science</i> , 2019, 364, 822-824.	12.6	6
18	Bacterial Outer Membrane Vesicles (OMVs)-Based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV. <i>Vaccines</i> , 2019, 7, 46.	4.4	38

#	ARTICLE	IF	CITATIONS
19	Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. <i>Emerging Microbes and Infections</i> , 2019, 8, 103-108.	6.5	42
20	Evolution of H5-Type Avian Influenza A Virus Towards Mammalian Tropism in Egypt, 2014 to 2015. <i>Pathogens</i> , 2019, 8, 224.	2.8	2
21	A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice. <i>Pathogens</i> , 2019, 8, 281.	2.8	4
22	Isolation and Characterization of a Distinct Influenza A Virus from Egyptian Bats. <i>Journal of Virology</i> , 2019, 93, .	3.4	42
23	Evidence of infection with avian, human, and swine influenza viruses in pigs in Cairo, Egypt. <i>Archives of Virology</i> , 2018, 163, 359-364.	2.1	24
24	Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	6.5	55
25	Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016. <i>Eurosurveillance</i> , 2017, 22, .	7.0	41
26	Surveillance for Coronaviruses in Bats, Lebanon and Egypt, 2013â€“2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 148-150.	4.3	15
27	Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus Isolated from a Dromedary Camel in Egypt. <i>Genome Announcements</i> , 2016, 4, .	0.8	17
28	Middle East respiratory syndrome coronavirus: a comprehensive review. <i>Frontiers of Medicine</i> , 2016, 10, 120-136.	3.4	49
29	Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. <i>Vaccine</i> , 2016, 34, 218-224.	3.8	13
30	Active Surveillance for Avian Influenza Virus, Egypt, 2010â€“2012. <i>Emerging Infectious Diseases</i> , 2014, 20, 542-551.	4.3	71
31	MERS Coronaviruses in Dromedary Camels, Egypt. <i>Emerging Infectious Diseases</i> , 2014, 20, 1049-1053.	4.3	259
32	Genetic and antigenic evolution of H9N2 avian influenza viruses circulating in Egypt between 2011 and 2013. <i>Archives of Virology</i> , 2014, 159, 2861-2876.	2.1	58
33	Anticancer activities of mushroom polysaccharides on chemically-induced colorectal cancer in rats. <i>Journal of Applied Pharmaceutical Science</i> , 2014, 4, .	1.0	9
34	Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. <i>Eurosurveillance</i> , 2013, 18, pii=20574.	7.0	278